Quercetin enhances apoptotic effect of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in ovarian cancer cells through reactive oxygen species (ROS) mediated CCAAT enhancer-binding protein homologous protein (CHOP)-death receptor 5 pathway

Liu Yi,1,3 Yang Zongyuan,1,3 Gong Cheng,1 Zhang Lingyun,2 Yu Guilian2 and Gong Wei2

1Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan; 2Department of Oncology, XiangYang Central Hospital, Hubei University of Arts and Science, XiangYang, China

Key words
CCAAT enhancer-binding protein homologous protein, death receptor 5, quercetin, reactive oxygen species, tumor necrosis factor-related apoptosis-inducing ligand

Correspondence
Gong Wei, Department of Oncology, XiangYang Central Hospital, Hubei University of Arts and Science, XiangYang 441021, China.
Tel: +86-710-369-0195; Fax: +86-710-369-0195;
E-mail: gongzhewei@sina.com

1These authors contributed equally to this work.

Funding information
National Science Foundation of China (81373433). National Science Foundation of Hubei province (2012FFB01906). Education Department of Hubei province for Young Talents Foundation (Q20132605).

Received October 29, 2013; Revised February 10, 2014; Accepted March 5, 2014

Cancer Sci 105 (2014) 520–527
doi: 10.1111/cas.12395

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) has been thought to have the strongest antitumor activity in a variety of tumor cell types, while exhibiting minimal cytotoxicity in most normal cells.1,2 Death receptor 5 (DR5; TRAIL-R2) and death receptor 4 (DR4; TRAIL-R1) are members of the TNF family that are activated by TRAIL.3,4 TRAIL induces formation of death inducing signal complexes.5 However, recent reports have shown that some cancer cells are resistant to the apoptotic effects of TRAIL.6 TRAIL resistant cells can be sensitized by chemotherapeutic drugs in vitro, indicating that combined therapy may be useful to treat TRAIL resistant cancer cells. Several reports have shown that the DR5 plays an important role in sensitizing cancer cells to apoptosis induced by TRAIL and chemotherapeutic agents.7

Numerous signaling molecules are known to trigger DR5 induction, including activation of inositol-requiring enzyme 1 (IRE1), PKR-like ER kinase (PERK), and activating transcription factor (ATF6).8,9 and the binding of CCAAT/enhancer binding protein (C/EBP) homologous protein (CHOP) transcription factor to DR5 promoter.10 Reactive oxygen species (ROS), a byproduct of normal metabolic processes and generated by exogenous sources, are integral components of cell signaling pathways.11 Important downstream mediators of ROS-induced signaling are the IRE112 such as JNK. ROS have also been shown to induce CHOP expression.13 Thus the agents that can modulate the expression of these signaling molecules can induce DR5 expression and might offer potential as anticancer agents. One of the potential sources of such agents includes natural products derived from “Mother Nature.” Natural products have played a significant role over the years in the discovery of cancer drugs; more than 70% of drugs are of natural origin.14 Quercetin (Fig. 1a) are polyphenols and a flavonoid that have been reported to have a broad spectrum of medicinal properties including anti-inflammatory, antimicrobial, antioxidant, anti-cancer, and cardioprotective properties.15 Therefore, the investigation of natural compounds with potential antiproliferative effects is a critical challenge in cancer drug discovery.16 Quercetin has been shown to have antiproliferative activity in breast cancer cell lines17 and to increase cell death in ovarian cancer cells.18 Quercetin has also been shown to inhibit tumor growth in vivo through induction of apoptosis, activation of caspase-3, CHOP and DR5. Overall, our data suggest that quercetin enhances apoptotic death of ovarian cancer cells to TRAIL through upregulation of CHOP-induced DR5 expression following ROS mediated endoplasmic reticulum-stress.
Quercetin is found naturally in fruits, vegetables, tea and other plant-derived foods and beverages. Experimental evidence suggests that quercetin have several potential anticancerous characteristics, including antioxidant, antiestrogenic, antiproliferative and anti-inflammatory properties. Furthermore, quercetin may have antitumor effects on human cervical cancer HeLa cells via AMP-activated protein kinase (AMPK) induced HSP70 and downregulation of epidermal growth factor receptor (EGFR). Quercetin induces apoptosis via AMPK activation and p53-dependent apoptotic cell death in HT-29 colon cancer cells. Although quercetin had been demonstrated to display a potent in vitro growth inhibition of several tumor cell lines, the molecular mechanism by which quercetin exerts anticancer effects has not been well understood. The combined results of previous studies and the present study show that quercetin can sensitize tumor cells to TRAIL by modulating signaling molecules that regulate apoptosis.

**Materials and Methods**

**Cell culture and viability assay.** SKOV-3, OVCAR-3, TOV-21G and HOSE cells were procured from China Center for Type Culture Collection (CCTCC, Wuhan, China), and cultured according to CCTCC guidelines. Cells (4 × 10^4 cells/mL) in 96-well plates were treated with appropriate amount of quercetin and TRAIL (25 ng/mL) for 24 h. Ten microliters of Cell Counting Kit (CCK) solution was added to each well and the plates were further incubated at 37°C for 1.5 h. Using Dojindo's highly water-soluble tetrazolium salt, the absorbance was measured at 450 nm with a reference wavelength at 650 nm using a microplate reader MR700 (Dynatech, Chantilly, VA, USA).

**Reagents and materials.** Antibody to caspase-3 was obtained from Imgenex (San Diego, CA, USA). Antibodies to caspase-9, c-FLIP, p-JNK, JNK, GRP78, and CHOP were purchased from Cell Signaling (Beverley, MA, USA). Antibody to p-eIF2α was from StressGen (Ann Arbor, MI, USA). Antibody to caspase-8 was obtained from Calbiochem (San Diego, CA, USA).
antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). DMEM and fetal bovine serum were obtained from Gibco-BRL (Grand Island, NY, USA). Polyvinylidene difluoride (PVDF, 0.22 mm) membrane was purchased from Bio-Rad (Hercules, CA, USA). [γ-32P] ATP was from BMS (Avenne, NY, USA). All the other reagents were obtained from Sigma (St. Louis, MO, USA).

**Apoptosis analysis.** Apoptosis was analyzed by FACS as previously described. After 5 × 10^5 cells/well were seeded to a 6-well plate for 24 h, the cells were then treated with or without quercetin and/or TRAIL (25 ng/mL) for 24 h. Then, the cells were harvested, washed with PBS, and stained with FITC-Aannexin V (Sigma) and propidium iodide (PI). The apoptosis of cells was analyzed by flow cytometry using Cell Quest Software.

**Measurement of reactive oxygen species generation.** Intracellular ATP detection. Cells (2 × 10^5 cells/well) in a 12-well dishes were treated with quercetin at various concentrations, and grown in 5% CO_2 and 95% air at 37°C. At the end of incubation, cells from each treatment were harvested and washed twice by PBS, and then resuspended in 500 μL of DiOC6 (1 μM) for the level of ΔΨ_m. Then cells were incubated at 37°C in a dark room for 30 min and analyzed immediately by flow cytometry as described previously.

**Transfection with siRNA.** We used HiPerFect transfection reagent for silencing CHOP. Scrambled siRNA was used as a siRNA control. Cells were plated and allowed to adhere for 24 h. On the day of transfection, 12 μL of transfection reagent was added to 25 nM siRNA in a final volume of 100 μL of culture medium. After 48 h, cells were treated with quercetin and then exposed to TRAIL for 24 h.

**Analysis of gene expression by real-time PCR.** Total RNAs were isolated using TRIzol reagent (Invitrogen) from tumor cells according to the manufacturer’s instructions. Quantitative real-time PCR for the CHOP, DR5 and GAPDH genes was performed using procedures previously described. The primer sequences were as follows: CHOP, sense 5'-GCACCTCCGACAGCCCTCTACCTCTC-3', antisense 5'-GTCTATCTCCAAACC TTCCTCCTGGC-3'; DR5, sense 5'-GCTCTCTCTGATCACCACAC-3', antisense 5'-CTGCACTGTGACTCTATG-3'; GAPDH, sense 5'-TCAATTGACTCTACTA CAATGGTTT-3', antisense 5'-GAAGATGGTGATGGGATTTC-3'. The results were expressed as the expression level of each gene relative to that of housekeeping gene GAPDH.

**Western blot analysis.** Following incubation of cells in the presence or absence of quercetin and/or TRAIL (25 ng/mL), cell lysates were subjected to electrophoresis under reducing conditions. Western blot analysis was performed using procedures previously described. Primary antibodies and horseradish peroxidase conjugated secondary antibodies were purchased from StressGen (Ann Arbor, MI, USA), SantaCruz Biotechnology (Santa Cruz, CA, USA), Calbiochem (San Diego, CA, USA) and Cell Signaling (Beverley, MA, USA), respectively.

**In vitro caspase-3 activity assay.** After appropriate treatment, active caspase activity was measured using a caspase activation kit according to the manufacturer’s protocol (R&D Systems, Minneapolis, MN, USA). Active caspase cleaves the peptide and releases chromophore pNA that can be detected spectrophotometrically at a wavelength of 405 nm.

**Xenograft assay.** Four- to six-week-old athymic nude mice were purchased from SLAC Laboratory Animal Company (Shanghai, China). The mice were maintained in the accredited animal facility of Tongji Medical College, and used for studies approved by the Animal Care and Use Committee of Tongji Medical College. About 5 × 10^5 SKOV-3 cells were injected subcutaneously into both right and left flanks. Thirty mice were assigned randomly to each group. Since each mouse was implanted with two xenografts, each group had 20 tumors. Two days after tumor implantation, mice in the control group received PBS, whereas mice in the treatment group received 2 μg/kg quercetin suspended in PBS by oral gavage and/or without TRAIL (100 ng, i.p.) every day. Beginning on the 7th day after cell implantation, tumor volume was measured thrice a week using vernier calipers until day 30 as previously described by us. At the termination of the experiment, mice were killed at 24 h after the last administration of compound. Tumor samples were fixed in paraformaldehyde.

**Immunohistochemistry.** Muscle tissues from the inoculation sites of the treated mice were surgically excised, embedded in paraffin, and stained with hematoxylin and eosin for histopathologic evaluation. For indirect immunostaining, fresh tissues were embedded in an optimum cutting temperature solution and cut into 10-μm sections. The sections were fixed by acetone and incubated overnight at 4°C with rabbit anti-human caspase-3 or CHOP or DR5 monoclonal antibody diluted at 1:100. Biotinylated rat anti-rabbit immunoglobulin G was used as the secondary antibody, followed by streptavidin-conjugated horseradish peroxidase in the third step. The antibodies were purchased from Santa Cruz.

**Intracellular ATP detection.** After exposure of the cells to quercetin or and TRAIL (25 ng/mL), equal amounts of cell lysates were subjected to the measurement of ATP level according to the manufacturer’s protocol (Promega, Madison, WI, USA).

**Statistical analysis.** The results are expressed as the mean value ± SD and are interpreted by ANOVA repeated measures test. Differences are considered statistically significant when P < 0.05.

**Result**

Quercetin showed potent cell growth inhibition of SKOV-3, OVCAR-3 and TOV-21G cells and sensitizes tumor cells to TRAIL-induced apoptosis. To investigate the effect of quercetin on TRAIL-induced apoptosis, SKOV-3, OVCAR-3 and TOV-21G cells were respectively exposed to 25 ng/mL of TRAIL with or without quercetin at various concentrations. It was found that combined treatment of the cells with both TRAIL and quercetin showed significantly higher cell death compared to TRAIL or quercetin alone (Fig. 1b). The IC50 values for quercetin combined with or without TRAIL in ovarian cancer cells such as SKOV-3, OVCAR-3 and TOV-21G were found to be 222.1 ± 5.64 μM versus 153.3 ± 4.03 μM, 217.2 ± 4.89 μM versus 147.4 ± 3.86 μM, and 237.6 ± 6.07 μM versus 159.4 ± 3.64 μM, respectively.

However, 200 μM quercetin did not significantly affect cell viability in normal ovarian cells (HOSE cells) (Fig. S1a). Flow cytometric analysis and Hoechst 33 258 staining tests further supported that combination of both TRAIL and quercetin could dramatically enhance cell apoptosis (Fig. 1c, Fig. S1b). The results indicated that apoptosis in SKOV-3, OVCAR-3 and
TOV-21G cells was induced at $14.85 \pm 2.93\%$, $11.99 \pm 2.33\%$, and $12.67 \pm 2.61\%$ by quercetin, at $9.42 \pm 1.75\%$, $8.53 \pm 1.21\%$, and $10.82 \pm 2.01\%$ by TRAIL, and at $36.42 \pm 5.04\%$, $30.34 \pm 4.54\%$, and $33.29 \pm 5.28\%$ by the combination of the two agents (Fig. 1c). In accordance with these results, activation of caspase-3, 8, 9, and PARP cleavage were significantly increased when the SKOV-3 cells were exposed to both TRAIL and quercetin (Fig. 1d,e). In Figure 1e, after SKOV-3 cells were treated with 0, 50, 100, and 200 µM quercetin combined with or without TRAIL (25 ng /mL) for 24 h, the activation of caspase-3 in a dose-dependent manner was $0.14 \pm 0.02$ ng/mL and $0.15 \pm 0.019$ ng/mL, $0.18 \pm 0.021$ ng/mL and $0.22 \pm 0.025$ ng/mL, $0.17 \pm 0.022$ ng/mL and $0.51 \pm 0.049$ ng/mL, and $0.165 \pm 0.018$ ng/mL and $0.87 \pm 0.06$ ng/mL; the activation of caspase-8 in a dose-dependent manner was $0.13 \pm 0.019$ ng/mL and $0.16 \pm 0.017$ ng/mL, $0.17 \pm 0.015$ ng/mL and $0.23 \pm 0.022$ ng/mL, $0.155 \pm 0.016$ ng/mL and $0.52 \pm 0.044$ ng/mL, and $0.17 \pm 0.017$ ng/mL and $0.81 \pm 0.68$ ng/mL, respectively. These results indicate that quercetin increases TRAIL-induced apoptosis in ovarian cancer cells.

**Combined quercetin and TRAIL treatment induces mitochondria dysfunction and downregulates the expression of various antiapoptotic proteins.** Many of the mitochondrial cell survival proteins such as XIAP, Bcl-2, Bcl-xL, and cFLIP have been shown to cause TRAIL resistance. To see the intrinsic activity of quercetin in mitochondria, SKOV-3 cells were treated with quercetin and the level of intracellular ATP was measured. As expected, quercetin dose dependently reduced ATP formation (Fig. 2a). Correspondingly, numerous pieces of evidence have shown that apoptosis is associated with the increase of intracellular ROS levels and the loss of $\Delta \Psi _{m}$ of mitochondria. The results indicated that quercetin significantly increased the intracellular ROS levels and decreased the levels of $\Delta \Psi _{m}$ in SKOV-3 cells in a dose-dependent course (Fig. 2b, c). These results indicate that quercetin significantly affects mitochondrial membrane potential. In addition, quercetin obviously inhibited Bcl-2, Bcl-xL, XIAP, and Survivin expression, whereas FLICE like inhibitory protein (cFLIP) was not significantly affected (Fig. 2d). These results raised the possibility that quercetin induced mitochondrial dysfunction and downregulation of some cell survival proteins could contribute to the enhancement of TRAIL induced apoptosis (Fig. S2a-d).

ROS is essential for potentiation of TRAIL-induced apoptosis by Quercetin. Reactive oxygen species has been implicated in the induction of DR5 and plays an important role in sensitizing cancer cells to apoptosis induced by TRAIL and chemotherapy agents. First, we investigated whether quercetin induced upregulation of death receptors requires ROS. As expected, induced DR5 expression was observed by the quercetin treatment in ovarian cancer cells (Fig. 3a). Moreover, quercetin induced DR5 expression and the level of ROS was suppressed by N-acetyl-L-cysteine (NAC), a ROS scavenger (Fig. 3b,c). Next, we examined the role of ROS in potentiation of TRAIL-induced apoptosis by quercetin. SKOV-3 cells were treated with NAC before quercetin and TRAIL treatment, as shown in Figure 3(d), the number of apoptotic cells induced by quercetin plus TRAIL was reduced from 39.5 ± 3.87% to 17.3 ± 2.01% when cells were pretreated with NAC. Overall, these results suggest that ROS play a critical role in potentiation of TRAIL-induced apoptosis by quercetin.

**Effect of ROS on quercetin induced ER stress in ovarian cells.** Mitochondrial stress is frequently accompanied by an endoplasmic reticulum stress (ER-stress) signaling. Upon ER-stress induction, three proteins could be activated: IRE1, PERK, and ATF6. Phosphorylation of c-Jun N-terminal kinase (JNK) and eIF2α also follows IRE1a and PERK activations, respectively. When the tumor cells were treated with quercetin for different times, it appeared that phosphorylation of IRE1α and JNK was significantly increased compared to other ER-associated proteins (Fig. 4a). GRP78 and CHOP expressions were reported to occur downstream of IRE1α. Our data showed that there was no effect on GRP78 expression while CHOP expression could be detected following quercetin treatment, suggesting that CHOP mediated pathway might be involved in quercetin-induced ER-stress and the subsequent apoptosis (Fig. 4b).

On the basis of the above data, we hypothesized that ER stress and apoptosis induced by quercetin in ovarian cancer cells could be due to ROS generation via JNK mediating CHOP. To verify this, when SKOV-3 cells were pretreated with NAC, quercetin induced JNK phosphorylation was inhibited (Fig. 4c, Fig. S1c), which prevented CHOP production in
SKOV-3 cells (Fig. 4d). On the other hand, CHOP production and JNK phosphorylation induced by quercetin was also inhibited by a selective JNK inhibitor (SP600125) (Fig. 4c,d). Moreover, only the joint of the JNK inhibitor and NAC completely abolished the effect of quercetin (Fig. 4c,d, Fig. S1d,e).

In Figure 4d, the protein levels for each sample were determined as a ratio to their corresponding β-actin levels, compared with the control group (0.37 ± 0.04), CHOP was decreased at 0.23 ± 0.02 by the NAC group, at 0.17 ± 0.02 by the JNK inhibitor group, and at 0.12 ± 0.01 by the combination of the two agents. Therefore, these results indicate that ROS are implicated in quercetin induced upregulation of CHOP via JNK activation, which may result from the suppression of quercetin induced ER stress.

CHOP is crucial for upregulating DR5 expression and enhances the TRAIL mediated apoptosis effect by Quercetin. CHOP, a resident chaperone in the ER, is a key regulator of DR5. (10,23) To determine in more detail how quercetin modulates the expression of DR5, SKOV-3 cells were treated with 200 μM quercetin for 24 h, and cell-surface expression of DR5 identified by real-time polymerase chain reaction (PCR) (upper) and western blot (lower) analysis. *P < 0.05 when compared to control. (b–d) SKOV3 cells were pre-exposed to N-acetyl-L-cysteine (NAC) for 1 h, washed off, labeled with 2’,7’-dichlorodihydrofluorescein diacetate (DCFH-DA), and then exposed to quercetin for 24 h. (b) The intracellular ROS levels were then measured by flow cytometry. (c) The whole-cell extracts were analyzed by Western blot using DR5 antibodies. (d) Apoptosis was measured by annexin-V/PI as described in Materials and Methods. *P < 0.05 when compared to control.

Fig. 3. Quercetin upregulates DR5 through mediation of reactive oxygen species (ROS). (a) Quercetin enhances cell-surface expression of DR5. Cells were treated with 200 μM quercetin for 24 h, and cell-surface expression of DR5 identified by real-time polymerase chain reaction (PCR) (upper) and western blot (lower) analysis. *P < 0.05 when compared to control. (b–d) SKOV3 cells were pre-exposed to N-acetyl-L-cysteine (NAC) for 1 h, washed off, labeled with 2’,7’-dichlorodihydrofluorescein diacetate (DCFH-DA), and then exposed to quercetin for 24 h. (b) The intracellular ROS levels were then measured by flow cytometry. (c) The whole-cell extracts were analyzed by Western blot using DR5 antibodies. (d) Apoptosis was measured by annexin-V/PI as described in Materials and Methods. *P < 0.05 when compared to control.

SKOV-3 cells (Fig. 4d). On the other hand, CHOP production and JNK phosphorylation induced by quercetin was also inhibited by a selective JNK inhibitor (SP600125) (Fig. 4c,d). Moreover, only the joint of the JNK inhibitor and NAC completely abolished the effect of quercetin (Fig. 4c,d, Fig. S1d,e). In Figure 4d, the protein levels for each sample were determined as a ratio to their corresponding β-actin levels, compared with the control group (0.37 ± 0.04), CHOP was decreased at 0.23 ± 0.02 by the NAC group, at 0.17 ± 0.02 by the JNK inhibitor group, and at 0.12 ± 0.01 by the combination of the two agents. Therefore, these results indicate that ROS are implicated in quercetin induced upregulation of CHOP via JNK activation, which may result from the suppression of quercetin induced ER stress.

CHOP is crucial for upregulating DR5 expression and enhances the TRAIL mediated apoptosis effect by Quercetin. CHOP, a resident chaperone in the ER, is a key regulator of DR5. (10,23) To determine in more detail how quercetin modulates the expression of DR5, SKOV-3 cells were treated with 200 μM quercetin for 24 h, and qPCR analysis was performed for the determination of CHOP expression. Quercetin significantly increased CHOP expression in a dose-dependent manner (Fig. 4b). To further confirm that CHOP regulates DR5 expression, SKOV-3 cells were transfected with CHOP siRNA, followed by quercetin. Knockdown of CHOP in SKOV-3 cells diminished quercetin induced increased production of DR5 (Fig. 5a). Moreover, CHOP knockdown greatly reduced caspase-3 and 9 activation as well as PARP cleavage in cells treated with both quercetin and TRAIL (Fig. 5b). Fluorescence-activated cell sorting analyses showed also that cell apoptosis was restored upon the depletion of CHOP by siRNA treatment (Fig. 5c). These findings suggest that CHOP upregulates DR5 expression, which could be one of the mechanisms by which quercetin enhances TRAIL induced apoptosis in ovarian cancer cells.

Quercetin exhibits antitumor activity in ovarian cancer cell xenografts. Based on the above results, we next investigated whether quercetin enhances TRAIL induced ovarian tumor apoptosis in vivo. To test this, we injected 5 × 10⁶ SKOV-3 cells subcutaneously on both right and left flanks of female athymic nude mice. The treated group received quercetin by oral gavage with or without TRAIL, while the control group received PBS. Tumor volume was recorded thrice a week using vernier calipers and weight of mice was recorded twice a week. Our results show that tumor growth was reduced by the quercetin treated group, whereas only quercetin in combination with TRAIL significantly suppressed the growth of ovarian tumors (Fig. 6a). Interestingly, the weight of mice from both groups did not differ significantly suggesting that quercetin was not toxic to the mice (Fig. 6b). To test whether quercetin enhances TRAIL-induced tumor apoptosis was associated with ER stress by CHOP/DR5 pathway in vivo. A feature of apoptosis was observed in the tumor sections stained with immunohistochemistry that detected cleaved-caspase-3, CHOP, and DR5 is significantly increased in combined quercetin and TRAIL treated tumor (Fig. 6c). Overall, these findings demonstrate that quercetin enhances TRAIL-induced apoptosis in vivo and is associated with CHOP/DR5 pathway.

Discussion

Although TRAIL, is one of the potent cytokines with the potential to kill cancer cells selectively, its use has limitations
because of the resistance that certain cancer types develop.\(^{(24)}\) Therefore, agents that are safe and can sensitize cancer cells to TRAIL are needed. Here we provide evidence that quercetin, a bioactive plant flavonoid, can sensitize human ovarian cancer cells to TRAIL. Since overexpression of DR5 in TRAIL-resistant cancer cells restored TRAIL sensitivity.\(^{(25)}\) Our results showed that quercetin causes a significant increase in the levels of DR5 protein in ovarian cancer cells. Interestingly, quercetin treatment did not affect the levels of other IAP (XIAP, cIAP1, and cIAP2), emphasizing the specific effect of quercetin on DR5 expression. The increased level of DR5 expression, leading to stimulation of the death receptor pathway, seems to be the cause of activation of caspase-3, caspase-8, caspase-9, and PARP. However, enhanced TRAIL-induced apoptosis by quercetin induced DR5 upregulation is associated with increased activation of the caspase pathway.\(^{(26)}\)

In the present study, we demonstrated that quercetin, which was originally isolated as a H\(^+\)-ATP synthase inhibitor,\(^{(27)}\) sensitized tumor cell killing by TRAIL. Flow cytometric assay showed that quercetin exposure can cause cell apoptosis of ovarian cancer cell, \(\Delta\Psi\text{$_m$}\) disruption, ROS generation, and cytochrome c release that, due to mitochondrial dysfunctions, affects mitochondrial function and vice versa. It was reported that mitochondrial dysfunction including as ROS overproduction, \(\Delta\Psi\text{$_m$}\) disruption, and ATP reduction could damage mitochondrial dynamics.\(^{(19)}\) In addition, in accordance with the previous reports demonstrating the relationship between quercetin-induced mitochondrial dysfunction and cell apoptosis,\(^{(28)}\) we also showed that quercetin repressed the mitochondrial survival proteins including Bcl-2, Bcl-xL, and Survivin, leading to the enhanced apoptosis of cancer cells to TRAIL. Considering the observations that overexpression of antiapoptotic Bcl-2, Bcl-xL, and Survivin has been shown to be linked to tumor cell resistance to TRAIL.\(^{(29,30)}\)

We found that one of the most important upstream signals required for the upregulation of death receptors is ROS. The result shown that quercetin induced the generation of ROS in ovarian cancer cells, use of ROS scavengers downregulated...
the expression of DR5 induced by quercetin, the potentiation of TRAIL-induced apoptosis by quercetin was also abrogated by the use of ROS scavengers. Moreover, given the report by Sciarretta et al. demonstrating that ROS is an important genomic response to ER stress and is characterized by the activation of three distinct signal transduction pathways mediated by PERK, IRE1 and ATF6. ROS scavengers inactivated JNKs and downregulated CHOP. Thus ROS generation is an upstream event that leads to JNK activation, in particular IRE1α activation and CHOP induction, which in turn are responsible for the increased upregulation of TRAIL receptors.

On the other hand, CHOP is thought to be one of the most important transcription factors that can directly bind to DR5 promoter region and regulate DR5 expression dynamically.

Our observations further revealed that induction of DR5 by the quercetin is mediated through CHOP upregulation. These observations are supported by earlier reports showing the role of ROS in upregulating CHOP and enhancing the effects of TRAIL.

Recent studies have shown that quercetin is a strong inducer of apoptosis in diverse cancer cells. However, it is unclear whether quercetin enhances TRAIL-induced apoptosis of ovarian cancer cells in vivo occurs in response to treatment with this compound in vitro. In the present study, our results show that induction of apoptosis by quercetin indeed occurred in vivo, which could be responsible for the inhibitory effects on tumor growth by quercetin. Furthermore, only TRAIL in combination with quercetin significantly suppressed the growth of ovarian tumors, suggesting that quercetin enhances sensitivity of cancer cells to the apoptotic agent TRAIL and its potential use as an anticancer agent or an adjunct to current cancer therapies. Consistent with the in vitro data, our in vivo results...
indicate that increasing of cleaved-caspase-3, CHOP, and DR5 is closely correlated with the reduction of SKOV-3 tumor xenografts, further supporting our notion.

Taken together, our study demonstrates that mitochondrial proteins (ROS) are mediating the apoptotic process, downstream or in parallel, CHOP might be a crucial player for DR5 upregulation and cancer cell killing by quercetin. IRE1α-JNK signaling could also be considered to be the major ER-stress pathway for quercetin-induced CHOP expression, thus contributing to the enhanced apoptotic death of ovarian cancer cells to TRAIL. Hence, quercetin could be an attractive candidate for combined chemotherapy against cancer. Future studies using clinically relevant animal models, however, are needed to fully realize the potential of this fascinating molecule in the prevention and treatment of cancer.

Acknowledgements

This work was supported by the National Science Foundation of China (Nos. 81373433), National Science Foundation of Hubei province (Nos. 2012FFB01906), and Education Department of Hubei province for Young Talents Foundation (Nos. Q20132605).

Disclosure

The authors have no conflict of interest.

References

1 Bhardwaj A, Aggarwal BB. Receptor mediated choreography of life and death. J Clin Immunol 2003; 23: 317–32.
2 Pan G, O’Rourke K, Chinnaiyan AM et al. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276: 111–3.
3 Kurbanov BM, Fecker LF, Geilen CC et al. Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4. Oncogene 2007; 26: 3364–77.
4 van Geelen CM, Pennarun B, Le PT et al. Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5. BMC Cancer 2011; 11: 39.
5 Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood 2012; 119: 651–65.
6 Ndizangue TO, Sebbagh M, Merino D et al. A mitochondrial block and expression of XIAP lead to resistance to TRAIL induced apoptosis during progression to metastasis of a colon carcinoma. Oncogene 2008; 27: 6012–22.
7 Kim EH, Yoon MJ, Kim SU et al. Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL induced apoptosis via CCAAT /enhancer-binding protein homologous protein dependent DR5 upregulation. Cancer Res 2008; 68: 266–75.
8 Kim JY, Kim EH, Park SS et al. Quercetin sensitizes human hepatoma cells to TRAIL-induced apoptosis via Sp1 mediated DR5 upregulation and proapoptotic mediated c-FLIPs downregulation. J Cell Biochem 2008; 105: 1386–98.
9 Kraskiewicz H, FitzGerald U. InterFering with endoplasmic reticulum stress. Trends Pharmacol Sci 2012; 33: 53–63.
10 Yamaguchi H, Wang HG. CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells. J Biol Chem 2004; 279: 45095–502.
11 Gupta SC, Hevia D, Patchva S et al. Uspades and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal 2012; 16: 1295–322.
12 Torres M, Forman HJ. Redox signaling and the MAP kinase pathways. BioFactors 2003; 17: 287–96.
13 Tang JR, Nakamura M, Okura T et al. Mechanism of oxidative stress-induced GADD153 gene expression in vascular smooth muscle cells. Biochem Biophys Res Commun 2002; 1: 1255–9.
14 Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 2012; 75: 311–35.
15 Gates MA, Twarogger SS, Hecht JL et al. A prospective study of dietary flavonoid intake and incidence of epithelial ovarian cancer. Int J Cancer 2007; 121: 2225–32.
16 Lee DH, Szczepanski M, Lee YJ. Role of Bax in quercetin induced apoptosis in human prostate cancer cells. Biochem Pharmacol 2008; 75: 2345–55.
17 Jung YH, Heo J, Lee YJ et al. Quercetin enhances TRAIL induced apoptosis in prostate cancer cells via increased protein stability of death receptor 5. Life Sci 2010; 86: 351–7.
18 Kim HJ, Kim SK, Kim BS et al. Apoptotic effect of quercetin on HT-29 colon cancer cells via the AMPK signaling pathway. J Agric Food Chem 2010; 58: 8643–50.
19 Szabadkai G, Bianchi K, Varnai P et al. Chaperone mediated coupling of endoplasmic reticulum and mitochondrial Ca2+ channels. J Cell Biol 2006; 175: 901–11.
20 Wei G, Zhang GM, Liu Y et al. IFN-γ withdrawal after immunotherapy potentiates B16 melanoma invasion and metastasis by intensifying tumor integrin αvβ3 signaling. Int J Cancer 2008; 123: 702–8.
21 Bodmer JL, Holler N, Reynard S et al. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2000; 2: 241–3.
22 Seol DW, Li J, Seol MH, Park SY, Talanian RV, Billiar TR. Signaling events triggered by tumor necrosis factor related apoptosis inducing ligand (TRAIL): caspase-8 is required for TRAIL-induced apoptosis. Cancer Res 2001; 61: 1138–43.
23 Oh YT, Liu X, Yue P et al. ERK/ribosomal S6 kinase (RSK) signaling positively regulates death receptor 5 expression through co-activation of CHOP and Elk1. J Biol Chem 2010; 285: 41310–9.
24 Dida F, Li Y, Iwao A et al. Resistance to TRAIL induced apoptosis caused by constitutional phosphorylation of Akt and PTK in acute lymphoblastic leukemia cells. Exp Hematol 2008; 36: 1343–53.
25 Reuss DE, Michä J, Hagenlocher C et al. Sensitivity of malignant peripheral nerve sheath tumor cells to TRAIL is augmented by loss of NF1 through modulation of MYC/MAD and is potentiated by curcumin through induction of ROS. PLoS ONE 2013; 8: e57152.
26 Tian X, Ye J, Alonso-Asanta M et al. Modulation of CCAAT/enhancer binding protein homologous protein (CHOP) dependent DR5 expression by nelfinavir sensitizes glioblastoma multiforme cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Biol Chem 2011; 286: 29408–16.
27 Lee SM, Moon J, Cho Y et al. Quercetin upregulates expressions of peroxisome proliferators activated receptor γ, liver X receptor α, and ATP binding cassette transporter A1 genes and increases cholesterol efflux in human macrophage cell line. Nutr Res 2013; 33: 136–43.
28 Zhang L, Fang B. Mechanisms of resistance to TRAIL induced apoptosis in cancer. Cancer Gene Ther 2005; 12: 228–37.
29 Song JT, An JY, Kwon YT, Lee YJ. Evidence for two modes of development of acquired tumor necrosis factor related apoptosis inducing ligand resistance. Involvement of Bcl-xL. J Biol Chem 2003; 278: 29408–16.
30 Sciarretta S, Zhao P, Shao D et al. Activation of Nox4 in the endoplasmic reticulum promotes cardiomyocyte autophagy and survival during energy stress through the PERK/eIF2α/ATF4 pathway. Circ Res 2013; 113: 1253–64.
31 Sugi B, Prasad S, Ravindr J et al. Capsazepine, a TRPV1 antagonist, sensitizes colorectal cancer cells to apoptosis by TRAIL through ROS-JNK-CHOP-mediated upregulation of death receptors. Free Radic Biol Med 2012; 53: 1977–87.

Supporting Information

Additional supporting information may be found in the online version of this article:

Fig. S1. Quercetin enhances TRAIL induced apoptosis in human ovarian cancer cells.

Fig. S2. Quercetin enhances TRAIL induced mitochondrial dysfunction and downregulation of some cell survival proteins in human ovarian cancer cells.